RxDoctor Payments Data

Katrina Baxter, NP

Family · Milwaukee, WINPI 1639435373

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,900 of the $12,942 with a category attached, or 76.5%. Cvrx, Inc. accounts for 82.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $9,454 and has fallen 95.4% since, to $439 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,942in general payments, 2019–2025

Across 109 payments — averaging $118.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$11K
  • Abbott$492
  • Novartis$358
  • Boehringer Ingelheim$267
  • AstraZeneca$209
  • Merck$204
  • plus $735 from 11 others

What the payments were for

  • Consulting fees$9,90076%
  • Travel & lodging$1271%
  • Food & beverage$2,91523%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,942 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$14,423
Medicare patients
74
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan61$83,925
JardianceEmpagliflozin44$64,980
FarxigaDapagliflozin Propanediol39$47,525
OzempicSemaglutide17$23,817
EliquisApixaban20$16,805
Bumetanide61$3,603
Spironolactone78$1,045
Rosuvastatin Calcium30$538
Torsemide26$422
Metoprolol Succinate26$279
Losartan Potassium28$188
Isosorbide Mononitrate ErIsosorbide Mononitrate17$154
Furosemide26$129
Amlodipine Besylate13$97
Atorvastatin Calcium16$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$358$83,92561 claims
Boehringer IngelheimJardiance$267$64,98044 claims
AstraZenecaFarxiga$209$47,52539 claims
Novo NordiskOzempic$174$23,81717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →